The United States is the only profit-motivated healthcare system in the world, and perhaps it is no coincidence that this country also has the most expensive healthcare of any nation. Americans spent $3.2 trillion on healthcare (almost $10,000 per person on average) in 2015, accounting for 17.8% of the country's gross domestic product (GDP). According to actuaries from the Centers for Medicare & Medicaid Services (CMS), that number will increase to 20.1% of the GDP by 2025, as more people age into Medicare and consume more healthcare services. Since the Patient Protection and Affordable Care Act (ACA) passed in 2010, the United States has succeeded in precipitously lowering our uninsured rate, but this progress has been accompanied by the unintended consequence of ever-increasing healthcare spending. An increase in insured individuals has led to a growth in demand for hospital services, doctors' office visits, and prescription medications.

Although the president's signature legislation played a role in the continued growth of healthcare spending, the ACA is not solely responsible for this unsustainable trend. Every stakeholder, including providers, health insurers, pharmacies, federal and state governments, patients, and others, has a financial interest in the business of healthcare. In a country founded on capitalism, where competition accelerates innovation and drives down costs in virtually every other sector of the economy, it makes sense that the United States could sustain a healthcare system based on the same principles. However, that theory has not been true in practice. Although virtually every stakeholder that contributes to the US healthcare system does so with the primary goal of helping patients and improving healthcare outcomes, their parallel objective to earn a profit (an entirely reasonable expectation) has often added unintended consequences and costs to an already complex system.

No sector of the healthcare economy wants to accept blame for skyrocketing costs, and so far, none has had to. Politicians point fingers at pharmaceutical manufacturers, who in turn blame health insurers and pharmacy benefit managers (PBMs). Doctors complain about regulations and protocols enforced by payers and health system administrators, while patients remain unsatisfied with the quality and cost of their care. It seems that no one is satisfied, yet everyone (except the patient) goes home with their share of the profit at the end of the day.

The central challenge facing the US healthcare system is not the motivation of stakeholders to earn a profit, but rather the misaligned incentives among healthcare stakeholders as outlined in Table 1, which drive up costs unnecessarily. Although at their core all healthcare stakeholders agree that enabling quality, cost-effective care for patients should be their primary concern, other factors often interfere. These misaligned incentives do not apply universally to every stakeholder, which adds more complexity to the system. Each stakeholder has different profit motivations that drive up the overall costs of healthcare.

Patients are the central figures in any healthcare system, and although they are often the victim of misaligned incentives, they also bear some responsibility for rising costs. Typically, patients are motivated to spend as little as possible out of pocket. They are conditioned to expect healthcare to be inexpensive or free, because the majority of their expenses are covered by a third-party payer (a commercial health insurance company or the government).

Table 1  Healthcare Stakeholders' Misaligned Incentives

<table>
<thead>
<tr>
<th>Stakeholder</th>
<th>Incentive</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient</td>
<td>Spends as little as possible out-of-pocket; relies on third-party payers for the majority of healthcare costs</td>
</tr>
<tr>
<td>Provider</td>
<td>Earnings income substantial enough to pay back student loans and justify the time and effort invested in patient care</td>
</tr>
<tr>
<td>Health insurer</td>
<td>Generates more in revenue than the company will spend on medical care for members</td>
</tr>
<tr>
<td>PBM</td>
<td>Collects service fees and earns a percentage of savings generated on behalf of customers</td>
</tr>
<tr>
<td>Government</td>
<td>Spends as little taxpayer money as possible while providing access to care for America’s most vulnerable populations</td>
</tr>
<tr>
<td>Pharmaceutical manufacturer</td>
<td>Generates enough income to earn a profit after recouping R&amp;D and marketing costs</td>
</tr>
</tbody>
</table>

PBM indicates pharmacy benefit manager; R&D, research and development.

Mr Branning is Adjunct Professor, Rutgers Graduate School of Business, and President, Managed Market Resources, Mt Olive, NJ; Ms Vater is Senior Client Consultant, Managed Market Resources.
Because patients may not value healthcare as a service in which they are willing to invest their own money upfront, they have little incentive to actively participate in reducing costs. Patients may be reluctant, for example, to make a dietary change to reduce cholesterol levels when a once-daily pill can achieve the same results.

And yet, compounding the problem, the opposite may also be true. This dynamic, which does not reward patients for being accountable for their health, and insulates them from the true cost of healthcare, is beginning to change, but without the anticipated positive results. Employers and health insurers have begun pushing patients toward high-deductible health plans that require patients to pay more for their care upfront. Although these plans reduce spending in the short-term, they may discourage patients from seeking necessary care, leading to costly complications down the road. According to a patient survey conducted by the Physicians Foundation in 2016, patients are increasingly fearful that they will not be able to afford necessary care as medical costs continue to grow. The survey respondents overwhelmingly pointed to prescription drugs as a primary cause for increased spending, with 59% selecting drugs as a key cost driver. By comparison, physicians were associated with increased medical spending by only 20% of the respondents.

Of note, patients’ perception directly contradicts research presented by CMS and by PricewaterhouseCoopers. In 2014, CMS found that the largest portions of healthcare spending were attributed to hospital care (32%), physician and clinical services (20%), and prescription drugs (10%). Similarly, PricewaterhouseCoopers predicts that in 2017, healthcare spending will be distributed differently, with nearly 50% spent on hospital inpatient and outpatient treatment, 30% spent on physicians, and 17% spent on prescription drugs (Table 2). As noted in the report by PricewaterhouseCoopers, “Drug spending is still a relatively small portion of overall health spending and, as such, concerns of ever-increasing cost growth from new cures may trigger false alarms.”

The gap between patient perception and actual spending on healthcare occurs because patients typically pay a disproportionate share of the cost of drugs compared with other healthcare expenses. According to the Pharmaceutical Research and Manufacturers of America, an organization that represents and promotes the interests of pharmaceutical manufacturers, on average, patients pay nearly 20% of their drug costs out of pocket, while contributing only 5% of the cost of care they receive in a hospital (Table 3). This discrepancy is the result of the patient’s health insurance benefit design, which disadvantages pharmaceuticals, even though they may contribute to lowering hospital spending if used correctly.

Pharmaceutical manufacturers are often at odds with payers and with PBMs, despite their shared focus on the patient’s best interest. Payers and PBMs work on behalf of patients to control the cost of pharmaceuticals. Their motivation is to collect more in premium dollars than they spend on healthcare services for their members. They negotiate with manufacturers for the best possible price and organize their formulary accordingly, making lower-cost drugs available to patients with a lower cost-sharing responsibility. By contrast, drug manufacturers charge a higher price for their drugs to account for payer coverage gaps, formulary placement and restrictions, and the rebates and discounts required in the distribution and reimbursement channel. In addition, pharmaceutical manufacturers need to recoup their substantial investment in research and development, as well as marketing and other expenditures needed to bring the drug to market and achieve uptake among physicians and patients. When accused of setting their prices too high, as has often been the case in recent years, manufacturers respond that the price they set is rarely (if ever) the price paid by patients, as a result of rebates and other discounts. Oddly enough, approximately only 1 in every 100 New Drug Applications makes it to the market, and little mention is made of these losses in the media.

Similar to pharmaceutical manufacturers, providers must also negotiate for reimbursement with public and private payers. In geographic markets where an insurer is a dominant player, physicians may have little choice but to accept the reimbursement offered by the insurer or risk going out of business because of a diminished volume of patients. Physicians must also follow the protocols put in
place by payers that are designed to improve the quality and consistency of care provided to a population of patients. This practice may limit physicians’ autonomy and may negatively affect individual patients whose circumstances do not fit the standard care model. Payers argue, however, that their oversight is necessary to prevent unnecessary charges that result from the fee-for-service reimbursement model that has been prominent for decades. In a fee-for-service model, providers are incentivized to provide more services, but not necessarily higher-quality care. Payer management serves as an agent for consumer protection, but budget constraints and rapid increases in healthcare spending have emphasized financial concerns.

The government has a slightly different motivation from other healthcare stakeholders, because it does not earn profit, but it seeks to save money where possible while providing access to care for America’s most vulnerable populations. In 2015, for the first time government-sponsored programs surpassed the private industry; these programs now represent the majority of healthcare spending in the United States. Medicare covers approximately 57 million elderly and disabled people, whereas Medicaid and the Children’s Health Insurance Program serve as a safety net for more than 70 million children and low-income adults. Medicaid is the largest single payer for maternity care, childbirth, mental health services, and long-term care in the United States. Despite the government’s strong negotiating leverage, which enables it to obtain substantial discounts from providers and pharmaceutical companies, taxpayers are paying more for their own healthcare and for subsidized care provided to Medicare and Medicaid beneficiaries. Americans with private health insurance spend $5380 per person (on average); by comparison, Medicare paid nearly $12,000 per enrollee, and Medicaid programs spent almost $8000 per member (on average) in 2015. The government has a lot at stake and has taken this responsibility seriously; in addition to playing the role of payer, it also serves as a regulator. This is a fairly recent stronghold linked to the ACA and its supporting regulations. Medicare, for example, has more pages of regulations than the Internal Revenue Service’s tax code, and is considerably more complex.

**Conclusion**

This complex and convoluted mess caused by misaligned incentives has led many experts to declare the failure of the capitalist experiment in healthcare and to call for a public option or a single-payer system. In fact, President Barack Obama recently encouraged Congress to add a public option to improve his signature legislation, the ACA. “Public programs like Medicare often deliver care more cost-effectively by curtailing administrative overhead and securing better prices from providers,” President Obama wrote in a July 2016 special communication in the *Journal of the American Medical Association*.

Although we do not advocate for a government-run solution to America’s healthcare-spending crisis, we understand the frustration that motivates supporters of this proposed solution. Instead, however, we would prefer to see the US healthcare system work as it was intended: with uninhibited consumer choices; with competition for business among providers, pharmacies, pharmaceutical manufacturers, and payers; and with taxpayer-funded and charitable financial support for those in need. It is the responsibility of all stakeholders to stop looking for a scapegoat and to begin participating in the solution.

**Author Disclosure Statement**

Mr Branning and Ms Vater are with Managed Market Resource, which provides consulting services to many pharmaceutical companies.

**References**

7. Thayer AM. More drugs are succeeding in clinical trials after a 15-year decline, chances are better that a drug will make it to the market. Chemical & Engineering News. 2016;94:13.